A total of 4033 patients scheduled for coronary angiography were randomized to receive pretreatment with prasugrel or no prasugrel. There were no significant differences in the primary endpoint ...

Pharmacodynamic data now suggest that additional platelet inhibition beyond that provided by either prasugrel or ticagrelor might be necessary. Of course, this study was not powered to detect ...

INDIANAPOLIS and TOKYO, Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort ...

But the new drug, prasugrel (Effient), is also more likely to cause potentially fatal bleeding. Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in ...

Compared with the overall study population, a higher risk of serious bleeding among prasugrel patients was most evident in three distinct patient populations that are readily identifiable ...

Also limiting that population could be the recommendations from the panel that prasugrel, to be marketed under the name Effient, not be given to patients over 75 years old or with a history of ...

Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...

The TIMI Study Group, having observed previously that prasugrel reduces MI in patients undergoing PCI, applied the new system to characterize the types of MI affected by prasugrel. More than ...

A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study - those identified as the "core clinical cohort" population - showed that treatment with prasugrel (in ...

Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure ...